查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球顯影劑市場：按類型、型態、方式、給藥途徑、指示 - 預測至 2029 年
市場調查報告書
商品編碼
1436830

全球顯影劑市場：按類型、型態、方式、給藥途徑、指示 - 預測至 2029 年

Contrast Media Market by Type (Iodinated Contrast Media), Form (Liquid, Powder), Modality (X-ray, CT, MRI, Ultrasound), Route of Administration (Oral, Rectal), Indication (Cancer, Neurological, GI, Musculoskeletal Disorders) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 279 Pages | 訂單完成後即時交付

價格
簡介目錄

2023年顯影劑市場規模將達63億美元。

到 2029 年，該市場預計將達到 97 億美元，預測期內複合年成長率為 7.5%。顯影劑是給接受 X光成像的患者施用的化學試劑，以增強影像並獲得更好的結果。慢性病患者通常需要診斷，而影像診斷是治療的很大一部分。因此，隨著慢性病盛行率的增加，需要顯影劑的手術預計也會增加，從而促進市場成長。

調查範圍
調查年份 2021-2029
基準年 2022年
預測期 2023-2029
考慮單位 金額（十億美元）
部分 按類型、型態、方式、給藥途徑、適應症、用途和最終用戶
目標區域 北美、歐洲、亞太等地區

顯影劑市場依形式分為 X 光、CT、MRI 和超音波。使用顯影劑的CT領域具有諸如需要使用顯影劑的CT檢查數量增加、成像解析度高、應用於心血管疾病、癌症、胃腸道疾病等廣泛領域等優點，和神經系統疾病。從那時起，我們取得了巨大的成長。

全球顯影劑市場依應用分為放射學、介入放射學和介入性循環系統。介入放射學領域預計將是顯影劑市場中成長率最高的。介入放射學領域需求的快速成長歸因於多種因素，包括CT、MRI和超音波等先進技術的引入，以及在各種醫療狀況的診斷中對微創治療的日益偏好。這是有因素的。

本報告研究了全球顯影劑市場，包括按類型、型態、模式、給藥途徑、適應症、應用、最終用戶、地區和進入市場的公司概況分類的趨勢。我正在總結。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 價值鏈分析
  • 供應鏈分析
  • 技術分析
  • 波特五力分析
  • 監管狀況
  • 專利分析
  • 2024-2025年重大會議和活動
  • 價格分析
  • 貿易分析
  • 生態系分析
  • 影響客戶業務的趨勢/干擾
  • 主要相關人員和採購標準

第6章顯影劑市場，依類型

  • 介紹
  • 碘化
  • 钆基
  • 微氣泡
  • 鋇基

第7章顯影劑市場，依型態

  • 介紹
  • 液體
  • 粉末
  • 其他

第8章顯影劑市場（按形式）

  • 介紹
  • X光
  • CT
  • MRI
  • 超音波

第9章顯影劑市場，依管理途徑

  • 介紹
  • 血管內途徑
  • 口服
  • 直腸
  • 其他

第 10 章顯影劑市場（按跡象）

  • 介紹
  • 循環系統疾病
  • 癌症
  • 胃腸道疾病
  • 肌肉骨骼疾病
  • 神經系統疾病
  • 腎臟疾病

第11章顯影劑市場，按應用

  • 介紹
  • 輻射
  • 介入放射學
  • 介入性心臟病學

第 12 章顯影劑市場（按最終用戶）

  • 介紹
  • 醫院、診所、門診手術中心
  • 影像診斷中心

第13章顯影劑市場（按地區）

  • 介紹
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第14章競爭形勢

  • 概述
  • 主要參與企業所採取的策略
  • 主要參與企業收益分析
  • 市場佔有率分析
  • 企業評價矩陣
  • Start-Ups/小型企業評估矩陣
  • 競爭基準化分析
  • 競爭場景
  • 品牌/產品比較：顯影劑市場

第15章 公司簡介

  • 主要參與企業
    • GE HEALTHCARE
    • BRACCO IMAGING SPA
    • BAYER AG
    • GUERBET
    • LANTHEUS MEDICAL IMAGING
    • UNIJULES LIFE SCIENCES LTD.
    • JB CHEMICALS & PHARMACEUTICALS LIMITED
    • SANOCHEMIA PHARMAZEUTIKA
    • TAEJOON PHARM CO., LTD.
    • JODAS EXPOIM
    • IMAX DIAGNOSTIC IMAGING LIMITED
    • YANGTZE RIVER PHARMACEUTICAL GROUP
    • LIVEALTH BIOPHARMA
    • BEIJING BEILU PHARMACEUTICAL CO., LTD.
  • 其他公司
    • UNISPIRE BIOPHARMA PRIVATE LIMITED
    • ARCO LIFESCIENCES（I）PVT. LTD.
    • STANEX DRUGS & CHEMICALS PVT. LTD.
    • REGE IMAGING & CINE FILMS PRIVATE LIMITED
    • K DIAM EXIM
    • ONKO ILAC SAN. VE TIC. AS
    • FRESENIUS KABI
    • BIEM ILAC SAN. VE TIC. AS
    • ADVACARE PHARMA

第16章附錄

簡介目錄
Product Code: MD 3577

The contrast media market is valued at an estimated USD 6.3 billion in 2023 and is projected to reach USD 9.7 billion by 2029 at a CAGR of 7.5% during the forecast period. Contrast media are chemical reagents that are administered to patients undergoing radiology imaging procedures to gain enhanced images and better results of the procedure. Patients with chronic conditions often require require diagnosis, imaging forms a major part of their treatment. Hence, with an increase in the prevalence of chronic conditions, the procedures that need contrast media are also expected to increase, hence enabling market growth.

Scope of the Report
Years Considered for the Study2021-2029
Base Year2022
Forecast Period2023-2029
Units ConsideredValue (USD) Billion
SegmentsType, Form, Modality, Route of Administration, Indication, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, and Rest of the World

"Computed Tomography (CT) segment is projected to witness highest growth rate in the contrast media market, by modality, during the forecast period."

The contrast media market is segmented into X-ray, CT, MRI, and Ultrasound, on the basis of modality. The CT segment in contrast media is experiencing significant growth, owing to rise in the number of CT examinations that need the use of contrast media, coupled with its benefits such as, high resolution imaging, applications across broad areas such as CVD, cancer, GI diseases, and neurological conditions, among others.

"Interventional Radiology segment is projected to register highest growth rate in the contrast media market, by application, during the forecast period."

The global contrast media market is bifurcated into radiology, interventional radiology, and interventional cardiology, based on application. The interventional radiology segment is expected to grow at the highest rate within the contrast media market. The surge in demand for interventional radiology procedures is attributed to various factors such as introduction of sophisticated technologies among CT, MRI and ultrasound modalities, coupled with rise in the preference for minimally invasive procedures for the diagnosis of various medical conditions.

"Asia Pacific: The fastest-growing region contrast media market."

The global contrast media market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging economies in the Asia Pacific region such as China and India have been significantly investing in the development of their existing healthcare infrastructure, coupled with the rising prevalence of chronic conditions. These factors are anticipated to provide growth opportunities for contrast media companies operating in this region.

The break-up of the profile of primary participants in the contrast media market:

  • By Company Type: Tier 1 - 35%, Tier 2 - 40%, and Tier 3 - 25%
  • By Designation: C-level - 45%, D-level - 29%, and Others - 26%
  • By Region: North America - 35%, Europe - 27%, Asia Pacific - 32%, Rest of the World- 6%

The key players in contrast media market are GE HealthCare (US), Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging (US), Unijules Life Sciences Ltd. (India), JB Pharma (India), Sanochemia Pharmazeutika (Germany), TAEJOON PHARM Co., Ltd. (South Korea), Jodas Expoim (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Livealth Biopharma Pvt. Ltd. (India), Unispire Biopharma Private Limited (India), Acro Lifesciences (I) Pvt. Ltd. (India), Stanex Drugs & Chemical Pvt. Ltd. (India), Beijing Beilu Pharmaceutical Co., Ltd. (China), Rege Imaging & Cine Films Private Limited (India), K DIAM EXIM (India), Onko Ylac San. ve Tic. A.Þ. (Turkey), Fresenius Kabi (Germany), Biem Ilac San. ve Tic. A.S. (Turkey), and AdvaCare (US).

Research Coverage:

This research report categorizes the contrast media market by type (iodinated contrast media, microbubble contrast media, gadolinium-based contrast media, and barium-based contrast media), form (liquid, powder, and other forms), modality (CT, X-ray, MRI, and ultrasound), route of administration (intravascular route, rectal route, oral route, and other routes of administration), indication (cancer, cardiovascular diseases, gastrointestinal disorders, neurological disorders, and musculoskeletal disorders, nephrological disorders), application (radiology, inteventional radiology, and interventional cardiology), end user (hospital, clinics, and ambulatory surgical centers, and diagnostics imaging centers), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the contrast media market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies; acquisitions, and partnerships. new product launches, and recent developments associated with the contrast media market. This report covers the competitive analysis of upcoming startups in the contrast media market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall contrast media market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising prevalence of chronic diseases, rising volume of CT and MRI examinations performed, growing number of approvals of contrast media, and rising number of diagnostic centers and hospitals), restraints (Side-effects and risks of allergic reactions associated with contrast media), opportunities (development of generic contrast media and increasing research on contrast media), and challenges (preference of alternative modalities that do not need contrast media and dearth of trained professionals) influencing the growth of the contrast media market
  • Product Development/Innovation: Detailed insights on research & development activities, and new product launches and approvals in the contrast media market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the contrast media market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the contrast media market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like GE HealthCare (US), Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging (US) among others in the contrast media market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 CONTRAST MEDIA MARKET SEGMENTATION
    • 1.3.2 REGIONAL SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 MARKET STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
    • FIGURE 5 REVENUE SHARE ANALYSIS
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 7 CONTRAST MEDIA MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
    • 2.5.1 MARKET ASSUMPTIONS
    • 2.5.2 GROWTH RATE ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT ANALYSIS
  • 2.8 RECESSION IMPACT

3 EXECUTIVE SUMMARY

    • FIGURE 9 CONTRAST MEDIA MARKET, BY TYPE, 2023 VS. 2029 (USD BILLION)
    • FIGURE 10 CONTRAST MEDIA MARKET, BY FORM, 2023 VS. 2029 (USD BILLION)
    • FIGURE 11 CONTRAST MEDIA MARKET, BY MODALITY, 2023 VS. 2029 (USD BILLION)
    • FIGURE 12 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2029 (USD BILLION)
    • FIGURE 13 CONTRAST MEDIA MARKET, BY INDICATION, 2023 VS. 2029 (USD BILLION)
    • FIGURE 14 CONTRAST MEDIA MARKET, BY APPLICATION, 2023 VS. 2029 (USD BILLION)
    • FIGURE 15 CONTRAST MEDIA MARKET, BY END USER, 2023 VS. 2029 (USD BILLION)
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CONTRAST MEDIA MARKET

4 PREMIUM INSIGHTS

  • 4.1 CONTRAST MEDIA MARKET OVERVIEW
    • FIGURE 17 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: CONTRAST MEDIA MARKET, BY END USER & COUNTRY (2022)
    • FIGURE 18 HOSPITALS, CLINICS, & AMBULATORY SURGERY CENTERS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
  • 4.3 CONTRAST MEDIA MARKET: REGIONAL MIX
    • FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.4 CONTRAST MEDIA MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 20 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • 4.5 CONTRAST MEDIA MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 21 CHINA AND INDIA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 CONTRAST MEDIA MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of chronic diseases
    • TABLE 2 CANCER INCIDENCE, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
    • TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2020 VS. 2030 VS. 2040
      • 5.2.1.2 Growing number of approvals of contrast media
      • 5.2.1.3 Rising volume of CT and MRI examinations performed
    • TABLE 4 NUMBER OF MRI EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2019-2021
    • TABLE 5 NUMBER OF CT EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2019-2021
      • 5.2.1.4 Growing number of diagnostic centers and hospitals
      • 5.2.1.5 Availability of reimbursement
      • 5.2.1.6 Increasing demand for early disease diagnosis
      • 5.2.1.7 Increasing funding by public-private organizations
    • TABLE 6 LIST OF BENEFICIARY HOSPITALS OF NHS WALES
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Side-effects and risks of allergic reactions associated with contrast media
    • TABLE 7 LIST OF SIDE-EFFECTS/REACTIONS TO CONTRAST MEDIA
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Generic contrast media
      • 5.2.3.2 Increasing research on contrast media
    • TABLE 8 INDICATIVE LIST OF RESEARCH STUDIES
      • 5.2.3.3 Growth opportunities in emerging economies
      • 5.2.3.4 Increasing demand for minimally invasive imaging procedures
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Preference for alternative modalities of imaging that do not require contrast media
      • 5.2.4.2 Restriction of linear gadolinium-based contrast media and product recalls
      • 5.2.4.3 Dearth of trained professionals
    • TABLE 9 US: METROPOLITAN AREAS WITH HIGH EMPLOYMENT LEVELS FOR RADIOLOGY TECHNOLOGISTS AND TECHNICIANS, 2022
      • 5.2.4.4 Shortage of contrast media
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 23 VALUE CHAIN ANALYSIS: CONTRAST MEDIA MARKET
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 24 SUPPLY CHAIN ANALYSIS: CONTRAST MEDIA MARKET
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 INTENSITY OF COMPETITIVE RIVALRY
    • 5.6.3 BARGAINING POWER OF BUYERS
    • 5.6.4 BARGAINING POWER OF SUPPLIERS
    • 5.6.5 THREAT OF SUBSTITUTES
  • 5.7 REGULATORY LANDSCAPE
    • TABLE 10 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING CONTRAST MEDIA MARKET
    • 5.7.1 EU REGULATIONS
    • 5.7.2 FDA REGULATIONS
    • 5.7.3 JPMA REGULATIONS
  • 5.8 PATENT ANALYSIS
    • FIGURE 25 PATENT ANALYSIS: IODINATED CONTRAST MEDIA
    • FIGURE 26 PATENT ANALYSIS: GADOLINIUM-BASED CONTRAST MEDIA
  • 5.9 KEY CONFERENCES & EVENTS IN 2024-2025
    • TABLE 11 LIST OF CONFERENCES & EVENTS IN CONTRAST MEDIA MARKET
  • 5.10 PRICING ANALYSIS
    • TABLE 12 AVERAGE SELLING PRICE OF CONTRAST MEDIA
  • 5.11 TRADE ANALYSIS
    • TABLE 13 IMPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS AND DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 14 EXPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS AND DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.12 ECOSYSTEM ANALYSIS
    • FIGURE 27 ECOSYSTEM ANALYSIS: CONTRAST MEDIA MARKET
    • TABLE 15 ROLE IN ECOSYSTEM
    • FIGURE 28 KEY PLAYERS OPERATING IN CONTRAST MEDIA MARKET
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
    • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
    • 5.14.2 BUYING CRITERIA
    • FIGURE 30 KEY BUYING CRITERIA FOR TOP END USERS
    • TABLE 17 KEY BUYING CRITERIA FOR END USERS

6 CONTRAST MEDIA MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 18 CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
  • 6.2 IODINATED CONTRAST MEDIA
    • 6.2.1 HIGH DEMAND FOR IODINATED CONTRAST MEDIA DUE TO HIGHER DOSAGE REQUIRED IN CT SCANS-KEY FACTOR DRIVING MARKET GROWTH
    • TABLE 19 IODINATED CONTRAST MEDIA MARKET, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 20 IODINATED CONTRAST MEDIA MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
  • 6.3 GADOLINIUM-BASED CONTRAST MEDIA
    • 6.3.1 SUSPICION REGARDING SAFETY PROFILE TO CHALLENGE MARKET GROWTH
    • TABLE 21 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 22 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
  • 6.4 MICROBUBBLE CONTRAST MEDIA
    • 6.4.1 EXTREMELY POPULAR AMONG PHYSICIANS WORLDWIDE
    • TABLE 23 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 24 MICROBUBBLE CONTRAST MEDIA MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
  • 6.5 BARIUM-BASED CONTRAST MEDIA
    • 6.5.1 ADVERSE EFFECTS ASSOCIATED WITH USE TO NEGATIVELY IMPACT MARKET
    • TABLE 25 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 26 BARIUM-BASED CONTRAST MEDIA MARKET, BY COUNTRY, 2021-2029 (USD MILLION)

7 CONTRAST MEDIA MARKET, BY FORM

  • 7.1 INTRODUCTION
    • TABLE 27 CONTRAST MEDIA MARKET, BY FORM, 2021-2029 (USD MILLION)
  • 7.2 LIQUID
    • 7.2.1 INCREASING ADOPTION OF EASY-TO-USE LIQUID FORM OF CONTRAST MEDIA ACROSS HOSPITALS AND DIAGNOSTIC CENTERS TO DRIVE MARKET
    • TABLE 28 LIQUID CONTRAST MEDIA MARKET, BY REGION, 2021-2029 (USD MILLION)
  • 7.3 POWDER
    • 7.3.1 EASE OF HANDLING, STORAGE, AND TRANSPORTATION TO FAVOR ADOPTION
    • TABLE 29 POWDER CONTRAST MEDIA MARKET, BY REGION, 2021-2029 (USD MILLION)
  • 7.4 OTHER FORMS
    • TABLE 30 CONTRAST MEDIA MARKET FOR OTHER FORMS, BY REGION, 2021-2029 (USD MILLION)

8 CONTRAST MEDIA MARKET, BY MODALITY

  • 8.1 INTRODUCTION
    • TABLE 31 NUMBER OF PROCEDURES PERFORMED, BY MODALITY, 2017-2020
    • TABLE 32 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2021-2029 (MILLION LITERS)
    • TABLE 33 CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
  • 8.2 X-RAY
    • 8.2.1 PRODUCTION OF HIGH-QUALITY IMAGES TO DRIVE MARKET
    • TABLE 34 UK: NUMBER OF X-RAY TESTS PERFORMED, 2012-2020
    • TABLE 35 CONTRAST MEDIA MARKET FOR X-RAY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 36 CONTRAST MEDIA MARKET FOR X-RAY, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.3 CT
    • 8.3.1 INCREASING NUMBER OF CT EXAMINATIONS TO PROPEL MARKET
    • TABLE 37 NUMBER OF CT SCANNERS PER 1,000 INHABITANTS, BY COUNTRY, 2020 VS. 2021
    • TABLE 38 UK: NUMBER OF CT SCANS PERFORMED, 2012-2020
    • TABLE 39 CONTRAST MEDIA MARKET FOR CT, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 40 CONTRAST MEDIA MARKET FOR CT, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.4 MRI
    • 8.4.1 ADVANTAGES OF MRI OVER OTHER IMAGING MODALITIES TO SUPPORT MARKET GROWTH
    • TABLE 41 NUMBER OF MRI UNITS PER 1,000 INHABITANTS, BY COUNTRY, 2019 VS. 2020 VS. 2021
    • TABLE 42 UK: NUMBER OF MRI TESTS PERFORMED, 2012-2020
    • TABLE 43 CONTRAST MEDIA MARKET FOR MRI, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 44 CONTRAST MEDIA MARKET FOR MRI, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.5 ULTRASOUND
    • 8.5.1 FLEXIBLE AND LOW-COST DIAGNOSTIC IMAGING MODALITY-KEY FACTORS DRIVING MARKET GROWTH
    • TABLE 45 UK: NUMBER OF ULTRASOUND TESTS PERFORMED, 2012-2020
    • TABLE 46 CONTRAST MEDIA MARKET FOR ULTRASOUND, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 47 CONTRAST MEDIA MARKET FOR ULTRASOUND, BY COUNTRY, 2021-2029 (USD MILLION)

9 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION

  • 9.1 INTRODUCTION
    • TABLE 48 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
  • 9.2 INTRAVASCULAR ROUTE
    • 9.2.1 WIDESPREAD USE OF INTRAVASCULAR ROUTE IN IMAGING MODALITIES TO DRIVE MARKET
      • 9.2.1.1 Intravenous (IV) route
      • 9.2.1.2 Intra-arterial (IA) route
    • TABLE 49 CONTRAST MEDIA MARKET FOR INTRAVASCULAR ROUTE, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 50 CONTRAST MEDIA MARKET FOR INTRAVASCULAR ROUTE, BY COUNTRY, 2021-2029 (USD MILLION)
  • 9.3 ORAL ROUTE
    • 9.3.1 USE OF ORAL CONTRAST MEDIA CAN LEAD TO PERFORATIONS IN GIT, LEADING TO PERITONITIS
    • TABLE 51 CONTRAST MEDIA MARKET FOR ORAL ROUTE, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 52 CONTRAST MEDIA MARKET FOR ORAL ROUTE, BY COUNTRY, 2021-2029 (USD MILLION)
  • 9.4 RECTAL ROUTE
    • 9.4.1 MILD DISCOMFORT ASSOCIATED WITH RECTAL CONTRAST MEDIA TO LIMIT MARKET GROWTH
    • TABLE 53 CONTRAST MEDIA MARKET FOR RECTAL ROUTE, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 54 CONTRAST MEDIA MARKET FOR RECTAL ROUTE, BY COUNTRY, 2021-2029 (USD MILLION)
  • 9.5 OTHER ROUTES
    • TABLE 55 CONTRAST MEDIA MARKET FOR OTHER ROUTES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 56 CONTRAST MEDIA MARKET FOR OTHER ROUTES, BY COUNTRY, 2021-2029 (USD MILLION)

10 CONTRAST MEDIA MARKET, BY INDICATION

  • 10.1 INTRODUCTION
    • TABLE 57 CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
  • 10.2 CARDIOVASCULAR DISEASE
    • 10.2.1 HIGH BURDEN OF CVD TO DRIVE MARKET
    • TABLE 58 CONTRAST MEDIA MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 59 CONTRAST MEDIA MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.3 CANCER
    • 10.3.1 ASIA PACIFIC MARKET TO REGISTER RELATIVELY HIGHER GROWTH OWING TO HIGH CANCER PREVALENCE IN REGION
    • TABLE 60 CANCER INCIDENCE, BY REGION, 2020 VS. 2035 (MILLION)
    • TABLE 61 CONTRAST MEDIA MARKET FOR CANCER, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 62 CONTRAST MEDIA MARKET FOR CANCER, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.4 GASTROINTESTINAL DISORDERS
    • 10.4.1 RISING PREVALENCE OF GI DISORDERS TO SUPPORT MARKET GROWTH
    • TABLE 63 CONTRAST MEDIA MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 64 CONTRAST MEDIA MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.5 MUSCULOSKELETAL DISORDERS
    • 10.5.1 RISING INCIDENCE OF WORK-RELATED MUSCULOSKELETAL DISORDERS TO SUPPORT MARKET GROWTH
    • TABLE 65 CONTRAST MEDIA MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 66 CONTRAST MEDIA MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.6 NEUROLOGICAL DISORDERS
    • 10.6.1 RISING PREVALENCE OF DEMENTIA TO DRIVE MARKET
    • TABLE 67 CONTRAST MEDIA MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 68 CONTRAST MEDIA MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.7 NEPHROLOGICAL DISORDERS
    • 10.7.1 RISING PREVALENCE OF ESRD TO DRIVE DEMAND FOR DIAGNOSTIC TOOLS
    • TABLE 69 CONTRAST MEDIA MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 70 CONTRAST MEDIA MARKET FOR NEPHROLOGICAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)

11 CONTRAST MEDIA MARKET, BY APPLICATION

  • 11.1 INTRODUCTION
    • TABLE 71 CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
  • 11.2 RADIOLOGY
    • 11.2.1 GROWING NUMBER OF DIAGNOSTIC PROCEDURES TO DRIVE MARKET
    • TABLE 72 CONTRAST MEDIA MARKET FOR RADIOLOGY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 73 CONTRAST MEDIA MARKET FOR RADIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
  • 11.3 INTERVENTIONAL RADIOLOGY
    • 11.3.1 INCREASING POPULARITY OF MINIMALLY INVASIVE PROCEDURES TO SUPPORT MARKET GROWTH
    • TABLE 74 CONTRAST MEDIA MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 75 CONTRAST MEDIA MARKET FOR INTERVENTIONAL RADIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
  • 11.4 INTERVENTIONAL CARDIOLOGY
    • 11.4.1 RISING INCIDENCE OF CARDIAC DISEASES TO DRIVE MARKET
    • TABLE 76 CONTRAST MEDIA MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 77 CONTRAST MEDIA MARKET FOR INTERVENTIONAL CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)

12 CONTRAST MEDIA MARKET, BY END USER

  • 12.1 INTRODUCTION
    • TABLE 78 CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
  • 12.2 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS
    • 12.2.1 INCREASING ADOPTION OF DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET
    • TABLE 79 CONTRAST MEDIA MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 80 CONTRAST MEDIA MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 12.3 DIAGNOSTIC IMAGING CENTERS
    • 12.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO PROPEL MARKET
    • TABLE 81 CONTRAST MEDIA MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 82 CONTRAST MEDIA MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2021-2029 (USD MILLION)

13 CONTRAST MEDIA MARKET, BY REGION

  • 13.1 INTRODUCTION
    • TABLE 83 CONTRAST MEDIA MARKET, BY REGION, 2021-2029 (USD MILLION)
  • 13.2 NORTH AMERICA
    • FIGURE 31 NORTH AMERICA: CONTRAST MEDIA MARKET SNAPSHOT
    • TABLE 84 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 85 NORTH AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 86 NORTH AMERICA: CONTRAST MEDIA MARKET, BY FORM, 2021-2029 (USD MILLION)
    • TABLE 87 NORTH AMERICA: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 88 NORTH AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 89 NORTH AMERICA: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 90 NORTH AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 91 NORTH AMERICA: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.2.1 US
      • 13.2.1.1 Rising incidence of chronic diseases to drive market
    • TABLE 92 US: KEY MACROINDICATORS
    • TABLE 93 US: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 94 US: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 95 US: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 96 US: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 97 US: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 98 US: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.2.2 CANADA
      • 13.2.2.1 Increasing investments in improving medical imaging to drive market
    • TABLE 99 CANADA: KEY MACROINDICATORS
    • TABLE 100 CANADA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 101 CANADA: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 102 CANADA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 103 CANADA: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 104 CANADA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 105 CANADA: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.2.3 RECESSION IMPACT ON NORTH AMERICAN CONTRAST MEDIA MARKET
  • 13.3 EUROPE
    • TABLE 106 EUROPE: NUMBER OF MRI UNITS PER 1,000,000 INHABITANTS, BY COUNTRY, 2021
    • TABLE 107 EUROPE: NUMBER OF MRI EXAMS PER 1,000 INHABITANTS, BY COUNTRY, 2021
    • TABLE 108 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 109 EUROPE: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 110 EUROPE: CONTRAST MEDIA MARKET, BY FORM, 2021-2029 (USD MILLION)
    • TABLE 111 EUROPE: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 112 EUROPE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 113 EUROPE: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 114 EUROPE: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 115 EUROPE: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.3.1 GERMANY
      • 13.3.1.1 Presence of well-developed diagnostic imaging infrastructure to support market growth
    • TABLE 116 GERMANY: KEY MACROINDICATORS
    • TABLE 117 GERMANY: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 118 GERMANY: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 119 GERMANY: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 120 GERMANY: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 121 GERMANY: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 122 GERMANY: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.3.2 FRANCE
      • 13.3.2.1 Increasing prevalence of cancer to propel market
    • TABLE 123 FRANCE: KEY MACROINDICATORS
    • TABLE 124 FRANCE: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 125 FRANCE: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 126 FRANCE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 127 FRANCE: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 128 FRANCE: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 129 FRANCE: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.3.3 UK
      • 13.3.3.1 Increasing investments in diagnostic imaging to boost market growth
    • TABLE 130 UK: KEY MACROINDICATORS
    • TABLE 131 UK: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 132 UK: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 133 UK: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 134 UK: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 135 UK: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 136 UK: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.3.4 ITALY
      • 13.3.4.1 Rising geriatric population to drive demand for diagnostic procedures
    • TABLE 137 ITALY: KEY MACROINDICATORS
    • TABLE 138 ITALY: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 139 ITALY: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 140 ITALY: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 141 ITALY: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 142 ITALY: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 143 ITALY: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.3.5 SPAIN
      • 13.3.5.1 Shortage of radiologists to restrain market growth
    • TABLE 144 SPAIN: KEY MACROINDICATORS
    • TABLE 145 SPAIN: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 146 SPAIN: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 147 SPAIN: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 148 SPAIN: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 149 SPAIN: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 150 SPAIN: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.3.6 REST OF EUROPE
    • TABLE 151 REST OF EUROPE: HEALTHCARE EXPENDITURE PER CAPITA, BY COUNTRY, 2021 VS. 2022
    • TABLE 152 REST OF EUROPE: NUMBER OF MRI AND CT UNITS AND SCANS, BY COUNTRY, 2021
    • TABLE 153 REST OF EUROPE: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 154 REST OF EUROPE: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 155 REST OF EUROPE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 156 REST OF EUROPE: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 157 REST OF EUROPE: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 158 REST OF EUROPE: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.3.7 RECESSION IMPACT ON EUROPEAN CONTRAST MEDIA MARKET
  • 13.4 ASIA PACIFIC
    • FIGURE 32 ASIA PACIFIC: CONTRAST MEDIA MARKET SNAPSHOT
    • TABLE 159 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 160 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 161 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY FORM, 2021-2029 (USD MILLION)
    • TABLE 162 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 163 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 164 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 165 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 166 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.4.1 CHINA
      • 13.4.1.1 High incidence of cancer and stroke to support market growth
    • TABLE 167 CHINA: KEY MACROINDICATORS
    • TABLE 168 CHINA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 169 CHINA: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 170 CHINA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 171 CHINA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 172 CHINA: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 173 CHINA: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.4.2 JAPAN
      • 13.4.2.1 Strong healthcare sector and high disease incidence to favor market growth
    • TABLE 174 JAPAN: KEY MACROINDICATORS
    • TABLE 175 JAPAN: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 176 JAPAN: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 177 JAPAN: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 178 JAPAN: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 179 JAPAN: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 180 JAPAN: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.4.3 INDIA
      • 13.4.3.1 Growing investments in radiology to propel market growth
    • TABLE 181 INDIA: KEY MACROINDICATORS
    • TABLE 182 INDIA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 183 INDIA: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 184 INDIA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 185 INDIA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 186 INDIA: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 187 INDIA: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.4.4 AUSTRALIA
      • 13.4.4.1 Increasing research activities to drive market
    • TABLE 188 AUSTRALIA: KEY MACROINDICATORS
    • TABLE 189 AUSTRALIA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 190 AUSTRALIA: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 191 AUSTRALIA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 192 AUSTRALIA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 193 AUSTRALIA: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 194 AUSTRALIA: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.4.5 REST OF ASIA PACIFIC
    • TABLE 195 NUMBER OF MRI AND CT UNITS PER MILLION POPULATION, BY COUNTRY, 2021
    • TABLE 196 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 197 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 198 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 199 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 200 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 201 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.4.6 RECESSION IMPACT ON ASIA PACIFIC CONTRAST MEDIA MARKET
  • 13.5 REST OF THE WORLD
    • TABLE 202 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 203 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 204 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY FORM, 2021-2029 (USD MILLION)
    • TABLE 205 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 206 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 207 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 208 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 209 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.5.1 LATIN AMERICA
      • 13.5.1.1 Lack of adequate healthcare infrastructure and poor insurance coverage to limit market growth
    • TABLE 210 LATIN AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 211 LATIN AMERICA: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 212 LATIN AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 213 LATIN AMERICA: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 214 LATIN AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 215 LATIN AMERICA: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.5.2 MIDDLE EAST & AFRICA
      • 13.5.2.1 High burden of chronic diseases to drive market
    • TABLE 216 ISRAEL: DIAGNOSTIC IMAGING DATA, 2022
    • TABLE 217 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 218 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 219 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 220 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 221 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 222 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.5.3 GCC COUNTRIES
      • 13.5.3.1 Increasing government investments in healthcare sector and growing pharmaceuticals industry to drive market
    • TABLE 223 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 224 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY MODALITY, 2021-2029 (USD MILLION)
    • TABLE 225 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
    • TABLE 226 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY INDICATION, 2021-2029 (USD MILLION)
    • TABLE 227 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 228 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 13.5.4 RECESSION IMPACT ON REST OF THE WORLD CONTRAST MEDIA MARKET

14 COMPETITIVE LANDSCAPE

  • 14.1 OVERVIEW
  • 14.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 229 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CONTRAST MEDIA MARKET
  • 14.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CONTRAST MEDIA MARKET
  • 14.4 MARKET SHARE ANALYSIS
    • TABLE 230 CONTRAST MEDIA MARKET: DEGREE OF COMPETITION
    • FIGURE 34 CONTRAST MEDIA MARKET SHARE, BY KEY PLAYER (2022)
  • 14.5 COMPANY EVALUATION MATRIX
    • 14.5.1 STARS
    • 14.5.2 EMERGING LEADERS
    • 14.5.3 PERVASIVE PLAYERS
    • 14.5.4 PARTICIPANTS
    • FIGURE 35 CONTRAST MEDIA MARKET: COMPANY EVALUATION MATRIX, 2022
    • 14.5.5 COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 231 FOOTPRINT ANALYSIS
    • TABLE 232 TYPE FOOTPRINT
    • TABLE 233 REGIONAL FOOTPRINT
  • 14.6 STARTUP/SME EVALUATION MATRIX
    • 14.6.1 PROGRESSIVE COMPANIES
    • 14.6.2 RESPONSIVE COMPANIES
    • 14.6.3 DYNAMIC COMPANIES
    • 14.6.4 STARTING BLOCKS
    • FIGURE 36 CONTRAST MEDIA MARKET: STARTUP/SME EVALUATION MATRIX, 2022
  • 14.7 COMPETITIVE BENCHMARKING
    • TABLE 234 CONTRAST MEDIA MARKET: KEY STARTUPS/SMES
  • 14.8 COMPETITIVE SCENARIO
    • 14.8.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 235 CONTRAST MEDIA MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020-DECEMBER 2023
    • 14.8.2 DEALS
    • TABLE 236 CONTRAST MEDIA MARKET: DEALS, JANUARY 2020-DECEMBER 2023
    • 14.8.3 OTHER DEVELOPMENTS
    • TABLE 237 CONTRAST MEDIA MARKET: OTHER DEVELOPMENTS, JANUARY 2020-DECEMBER 2023
  • 14.9 BRAND/PRODUCT COMPARISON: CONTRAST MEDIA MARKET
    • TABLE 238 BRAND/PRODUCT COMPARISON (IODINATED CONTRAST MEDIA)
    • TABLE 239 BRAND/PRODUCT COMPARISON (GADOLINIUM-BASED CONTRAST MEDIA)

15 COMPANY PROFILES

(Business overview, Products offered, Recent developments & MnM View)**

  • 15.1 KEY PLAYERS
    • 15.1.1 GE HEALTHCARE
    • TABLE 240 GE HEALTHCARE: BUSINESS OVERVIEW
    • FIGURE 37 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
    • 15.1.2 BRACCO IMAGING SPA
    • TABLE 241 BRACCO IMAGING SPA: BUSINESS OVERVIEW
    • 15.1.3 BAYER AG
    • TABLE 242 BAYER AG: BUSINESS OVERVIEW
    • FIGURE 38 BAYER AG: COMPANY SNAPSHOT (2022)
    • 15.1.4 GUERBET
    • TABLE 243 GUERBET: BUSINESS OVERVIEW
    • FIGURE 39 GUERBET: COMPANY SNAPSHOT (2022)
    • 15.1.5 LANTHEUS MEDICAL IMAGING
    • TABLE 244 LANTHEUS MEDICAL IMAGING: BUSINESS OVERVIEW
    • FIGURE 40 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT (2022)
    • 15.1.6 UNIJULES LIFE SCIENCES LTD.
    • TABLE 245 UNIJULES LIFE SCIENCES LTD.: BUSINESS OVERVIEW
    • 15.1.7 J.B. CHEMICALS & PHARMACEUTICALS LIMITED
    • TABLE 246 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: BUSINESS OVERVIEW
    • FIGURE 41 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2023)
    • 15.1.8 SANOCHEMIA PHARMAZEUTIKA
    • TABLE 247 SANOCHEMIA PHARMAZEUTIKA: BUSINESS OVERVIEW
    • 15.1.9 TAEJOON PHARM CO., LTD.
    • TABLE 248 TAEJOON PHARM CO., LTD.: BUSINESS OVERVIEW
    • 15.1.10 JODAS EXPOIM
    • TABLE 249 JODAS EXPOIM: BUSINESS OVERVIEW
    • 15.1.11 IMAX DIAGNOSTIC IMAGING LIMITED
    • TABLE 250 IMAX DIAGNOSTIC IMAGING LIMITED: BUSINESS OVERVIEW
    • 15.1.12 YANGTZE RIVER PHARMACEUTICAL GROUP
    • TABLE 251 YANGTZE RIVER PHARMACEUTICAL GROUP: BUSINESS OVERVIEW
    • 15.1.13 LIVEALTH BIOPHARMA
    • TABLE 252 LIVEALTH BIOPHARMA PVT. LTD.: BUSINESS OVERVIEW
    • 15.1.14 BEIJING BEILU PHARMACEUTICAL CO., LTD.
    • TABLE 253 BEIJING BEILU PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
  • *Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
  • 15.2 OTHER PLAYERS
    • 15.2.1 UNISPIRE BIOPHARMA PRIVATE LIMITED
    • 15.2.2 ARCO LIFESCIENCES (I) PVT. LTD.
    • 15.2.3 STANEX DRUGS & CHEMICALS PVT. LTD.
    • 15.2.4 REGE IMAGING & CINE FILMS PRIVATE LIMITED
    • 15.2.5 K DIAM EXIM
    • 15.2.6 ONKO ILAC SAN. VE TIC. A.S.
    • 15.2.7 FRESENIUS KABI
    • 15.2.8 BIEM ILAC SAN. VE TIC. A.S.
    • 15.2.9 ADVACARE PHARMA

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS